Frontline Progress Against Cancer: Affimed to Showcase Promising Clinical Advances at 2024 ASH Annual Meeting’
Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology pioneer, is poised to make a significant impact at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, held from December 7-10, 2024, in San Diego, California. The German-based biopharmaceutical company will present three pivotal abstracts highlighting advancements in their clinical pipeline specifically tailored to tackle leukemia and lymphoma.
The centerpiece of Affimed’s presentation is the eagerly anticipated oral session, during which results from the AFM28 phase 1 dose escalation study will be unveiled. This study focuses on patients with relapsed or refractory acute myeloid leukemia (AML), a challenging condition with limited treatment options. The company will showcase promising efficacy coupled with robust safety data, underscoring the therapeutic potential of AFM28, one of Affimed’s innovative innate cell engagers (ICE).
These data represent a pivotal step forward in cancer therapy, highlighting the capacity of AFM28 to harness innate immunity to target malignant cells more effectively. By leveraging the power of the immune system’s natural killer (NK) cells, AFM28 offers a cutting-edge approach to clearing leukemic cells from the body.
In addition to the oral presentation, Affimed will contribute to the scientific discourse through a poster presentation that turns the spotlight on preclinical work with AFM28. The poster will present compelling in vitro evidence demonstrating the efficacy of AFM28 in concert with both patient-derived autologous NK cells and allogeneic NK cells from healthy volunteers. This combination therapy could herald a new era of tailored, target-specific interventions for leukemia patients.
Affimed’s endeavors at the ASH Annual Meeting exemplify its commitment to giving patients back their innate ability to combat cancer. By pioneering innovative solutions and exploring synergistic therapeutic strategies, Affimed continues to push the boundaries of what is possible in immuno-oncology, fostering hope and optimism for patients and their families worldwide.
As the world eagerly anticipates the full presentations at ASH, Affimed is positioned at the forefront of oncology research, enabling immune breakthroughs that could redefine cancer treatment paradigms and deliver transformative outcomes.
Comments